| Literature DB >> 1115162 |
K E Anderson, L P Bengtsson, I Gustafson, I Ingemarsson.
Abstract
The uterine and cardiovascular responses to the adrenergic beta2-receptor stimulator terbutaline (TRB) were investigated in 14 patients in normal term labor. TRB, administered intravenously at a rate of 10 to 20 mug per minute, effectively inhibited uterine activity in advanced labor and also expulsion. Intravenous injection of TRB, 250 mug, diminished oxytocin-induced uterine hyperactivity. No serious side effects of the drug were observed; the circulatory effects were minimal, except for a tolerable maternal tachycardia. The mode of action and clinical application of TRB for inhibition of unwanted uterine activity are discussed.Entities:
Mesh：
Substances：
Year: 1975 PMID： 1115162 DOI： 10.1016/0002-9378(75)90459-7
Source DB: PubMed Journal: Am J Obstet Gynecol ISSN： 0002-9378 Impact factor: 8.661